The effects of cyclosporin A (cyA) on human polymorphonuclear leukocyte function, including phagocytosis, its associated metabolic burst, bacterial killing, and chemotaxis, were evaluated. Both Pseudomonas aeruginosa and Staphylococcus aureus were used as test particles. Polymorphonuclear leukocytes incubated in 10 and 50 ,ug of cyA per ml behaved normally with respect to phagocytosis and hexose monophosphate shunt activity at both high (10:1) and low (2:1) S. aureus/leukocyte ratios. With a small bacterial inoculum, killing of S. aureus was slightly impaired at early times only in the presence of 50 ,ug of cyA per ml. Phagocytosis and killing of P. aeruginosa with both large and small bacterial inocula were unaffected by cyA. Chemotaxis was within normal limits under all conditions. In addition, polymorphonuclear leukocytes from four renal transplant recipients receiving both cyA and prednisone demonstrated normal metabolic bursts and bacterial killing with both small and large inocula of S. aureus.
Cyclosporine A (cyA) is a fungal metabolite that is undergoing extensive evaluation as an immunosuppressive agent in organ transplantation (9, 11, 14) . Previous immunosuppressive regimens required cytotoxic chemotherapy combined with high doses of corticosteroids. These drugs have many effects (5) , with the most significant complication being infection (15) . cyA does not cause neutropenia (1) , and concomitant steroid dosage is usually much smaller (9) . At the University of Pittsburgh School of Medicine, cyA and prednisone are being used as immunosuppressive therapy for liver, heart, and kidney allografts. One case of deepseated Staphylococcus aureus infection and four cases of aspergillosis have occurred in patients in the posttransplant period (4a) . As these infections are reminiscent of those seen in chronic granulomatous disease (3, 7) , a condition in which human polymorphonuclear neutrophil (PMN) killing is markedly abnormal, a study of the effect of cyA on PMN function seemed to be in order.
MATERIALS AND METHODS
Human PMNs and monocytes were obtained from normal donors by layering heparinized whole blood over a Ficollsodium diatrizoate gradient (Sigma Chemical Co., St. Louis, Mo.) (2) . The erythrocytes-PMN-rich fraction was harvested, purified by sedimentation through dextran followed by hypotonic lysis of residual erythrocytes (4) glucose-cyA, and 10% serum. Samples were removed at 0, 45, 90 and 120 min, and the phagocytes were lysed by distilled water. After serial dilutions, 0.01-ml samples were dropped on Trypticase soy agar, and sterile 18-mm-diameter glass cover slips were placed on the drops. Bacterial killing was determined as above. Controls included bacteria, serum, and HBSS-cyA without phagocytes; bacteria and serum plus the diluent for cyA; and phagocytes, bacteria, and serum. Chemotaxis was measured in a modified 48-well microBoyden chamber (6) The effect of cyA on bacterial killing of S. aureus D2C at inocula of 2:1 and 10:1 at 45, 90, and 120 min is shown in Fig.   1 and 2. cyA at 10 p.g/ml had no significant effect on bacterial killing with a small (2:1) or a large (10:1) inoculum at any incubation time. cyA at 50 p.g/ml had a small, but significant, 10 ,ug/ml likewise had no effect on PMN phagocytosis or killing of P. aeruginosa with a large or small bacterial inoculum.
The effect of cyA on hexose monophosphate shunt activity is shown in Table 1 . There was no significant reduction in activity at either concentration of cyA with a small (2:1) or large (10:1) inoculum of S. aureus.
The effect of cyA on PMN and monocyte chemotaxis is shown in Table 2 . Neither PMN nor monocyte chemotaxis to FMLP or ZAP was altered by cyA.
Four patients who had received renal transplants were treated with cyA for 8 to 11 days when blood was obtained for leukocyte function studies. Evaluations of bacterial killing and hexose monophosphate shunt activity are shown in Table 3 . Although there was considerable patient-topatient variability, the mean activity was not significantly impaired for bacterial killing or metabolic activation at low or high bacterium/PMN ratios. One of the patients, however, appeared to show markedly reduced bacterial killing at an S. aureuslPMN ratio of 2:1 but not at 10:1. Hexose monophosphate shunt activity was not evaluated in this patient. (16) . The act of phagocytosis is accompanied by a respiratory and metabolic burst in which cellular oxygen consumption is markedly increased and glucose is channelled through the hexose monophosphate shunt pathway (12) . We therefore examined the effect of cyA on different facets of this defense system. The 50-,ug/ ml concentration of cyA represents an amount ca. 45 times the peak blood level and 100 times the steady-state level attained after the usual maintenance dose of 10 mg/kg per day in humans (13) . Neither chemotaxis, phagocytosis of S. aureus, nor hexose monophosphate shunt activity was impaired at these high concentrations. Interestingly, intracellular killing of S. aureus was diminished at early times with low but not with high bacterial ratios.
We also examined the effect of cyA on PMN phagocytosis and killing of P. aeruginosa. The reasons for choosing this organism were twofold. First, gram-negative rods are a major cause of morbidity and mortality in the posttransplant period (10, 15) . Second, PMN killing of P. aeruginosa is not dependent on oxidative killing mechanisms, as the bacteria are killed effectively by PMNs in an anaerobic environment (12) . We found no significant effect on phagocytosis or killing with a large or small bacterial inoculum at doses of 10 and 50 ,ug of cyA per ml. In contrast to the data from when S. aureus was used, no differences were found in any parameters studied at early times.
Our in vitro data were further corroborated by examining PMNs and serum from patients maintained on both cyA and prednisone. Again, no effect on bacterial killing or hexose monophosphate shunt activity was found. These studies are encouraging and lend additional support for the optimism surrounding cyA. 
